Clinical Trials Logo

RSV Infection clinical trials

View clinical trials related to RSV Infection.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06008457 Completed - Clinical trials for COVID-19 Respiratory Infection

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

Start date: April 17, 2023
Phase:
Study type: Observational [Patient Registry]

To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms of viral respiratory infection consistent with influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV) and/or SARS-CoV-2 (C-19).

NCT ID: NCT05727202 Completed - Clinical trials for SARS-CoV-2 Infection

Project STARFISH - PRJ0002679

STARFISH
Start date: February 20, 2023
Phase:
Study type: Observational

This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.

NCT ID: NCT05587478 Completed - RSV Infection Clinical Trials

A Study of EDP-323 in Healthy Subjects

Start date: September 29, 2022
Phase: Phase 1
Study type: Interventional

This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.

NCT ID: NCT05268939 Completed - COVID-19 Clinical Trials

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

INSPIRE-2
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites. Subjects presenting with symptoms suggestive of COVID-19 and/or Influenza and/or RSV will be consented and asked to donate swab sample(s) for testing in the device(s) under evaluation.

NCT ID: NCT05118386 Completed - RSV Infection Clinical Trials

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

Start date: November 16, 2021
Phase: Phase 1
Study type: Interventional

Gates MRI-RSM01-101 was a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, occurrence of Anti-drug antibody (ADA), and assessment of neutralizing antibody against RSV after administration of single intravenous or intramuscular doses of RSM01 to healthy adults.

NCT ID: NCT05070975 Completed - Bronchiolitis Clinical Trials

Severity of RSV Infections in Twins

TwinSeVeRS
Start date: November 5, 2021
Phase:
Study type: Observational

Respiratory syncytial virus (RSV) infection is the most common cause of severe lower respiratory tract infection (LRTI) in the pediatric population worldwide. Age at the time of infection, prematurity, multiparity, exposure to smoke and the level of passive immunity transmitted at birth are the main risk factors for lower respiratory infection associated with RSV. Other factors, including the innate immune response, respiratory microbiota, and intra-host viral heterogeneity, may also affect outcomes but are not fully considered in RSV infection. Exploring the impact of these factors is difficult due to the heterogeneity of the population which makes statistical adjustment difficult. Thus, twin models are useful in understanding the impact of the host on the environment, as twins often share similar exposure to infection and many risk factors, but not all are ie different prenatal and postnatal conditions, differential transfer of maternal antibodies and the genetic makeup of heterozygotes.

NCT ID: NCT04944160 Completed - RSV Infection Clinical Trials

Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) Epidemic

IPCoVRS
Start date: March 15, 2021
Phase:
Study type: Observational

The magnitude of seasonal Respiratory Syncytial Virus (RSV) epidemics brings each year new logistical challenges for the hospitalization of young infants with bronchiolitis that overwhelm hospital capacities and lead to specific winter plans with deprogramming and mobilization of human and logistical resources. The Covid-19 pandemic has changed the way winter epidemics are presented. For example, the seasonal RSV epidemic was shifted by several months in Lyon, with an impression of a lower incidence of hospitalized cases, with a population of older children and with fewer signs of clinical severity. This is largely attributable to the widespread use of barrier gestures and social distancing measures, known as "Non-Pharmacological Interventions" (NPI). Given the magnitude of the reduction of the RSV epidemic, it is legitimate to analyze the benefits of NPIs to draw lessons for maintaining preventive measures around RSV-vulnerable populations; moreover, new preventive pharmacological interventions are soon to be marketed, whether they are particularly refined and long half-life anti-RSV monoclonal antibodies, RSV vaccines for mothers or for newborns and infants. In this perspective, it is crucial to properly define the populations at risk of severe disease to establish a legitimate hierarchy in the implementation of different preventive strategies. The study of the RSV epidemic is a high potential model because of the convergence of epidemiological, virological, and pharmacological knowledge. However, the study of the impact of the pandemic on the epidemiology of rhinovirus also seems promising because, for reasons unknown to date, it seems that the pandemic did not have the same reducing impact on the rhinovirus epidemic; in the latter case, the interest is to confirm the resistance of this virus and to look for more fundamental explanations, for example, on viral interactions.

NCT ID: NCT04871724 Completed - RSV Infection Clinical Trials

Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Start date: March 12, 2021
Phase: Phase 1
Study type: Interventional

A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

NCT ID: NCT04752644 Completed - RSV Infection Clinical Trials

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Start date: February 22, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants

NCT ID: NCT04690335 Completed - RSV Infection Clinical Trials

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

Start date: December 29, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.